|Medi-Jector is used to take TEV-TROPIN® brand human growth hormone|
The company has not been profitable in recent years. This is to be expected as they are still largely in their research and development phase. Still they have products currently selling and many more products in the pipeline. As a result, Antares has been able to reduce loss over the past three years from $10M in FY 2009 to $6M in FY 2010 and finally to $4M in FY2011. That is an over 50% reduction in losses in two years. While you may argue that this is evidently possible if you don't spend any money, but the company has a number of products with significant partners in the pipeline. These partners include Jazz, Watson, TEVA, and most notably Pfizer. Also, a quick look at the 2011 10-K, shows that they do not have any long term debt. In fact, they have assets of $40M versus liabilities of $10M.
|ATRS Product Pipelines (from the company's website)|
Disclaimer: This article is written for informational purposes only and isn't intended as investment advice.
Disclosure: I am long ATRS.